Novo Nordisk A/S (NVO) News Today

Novo Nordisk A/S (NYSE:NVO) shares remain volatile as investors weigh a raised 2026 outlook against weaker-than-expected Wegovy pill sales, intensifying competition from Eli Lilly and concerns about execution. The stock has been trading above its 200-day moving average but remains well below its 52-week high.

• Positive Sentiment: Novo Nordisk raised its full-year sales and profit outlook for the second time this year. Management cited accelerating demand for the Wegovy pill and continued growth in obesity care, while recent coverage noted that second-quarter revenue and earnings exceeded analyst expectations. NVO Q2 Earnings Call Centers on Wegovy Pill and Outlook Lift
• Positive Sentiment: A Texas judge dismissed antitrust claims alleging Novo and Eli Lilly improperly restricted access to compounded GLP-1 weight-loss drugs. The ruling reduces a potential legal overhang for Novo’s obesity-drug business. Lilly and Novo Win a Key GLP-1 Antitrust Fight
• Positive Sentiment: The company declared a dividend of $0.5786 per share for investors of record August 17, payable August 25. The payout may provide some support for income-focused investors, although the reported yield in the announcement appears anomalous.
• Neutral Sentiment: CEO Mike Doustdar and CFO Karina Hertmann are emphasizing a reset in investor expectations and a more disciplined approach to growth after a difficult period. Their comments could help rebuild confidence, but they also underscore pressure to improve execution and regain momentum. Novo Nordisk CEO resets expectations for Wegovy's explosive growth
• Neutral Sentiment: Novo appointed Omnicom as its U.S. media-buying agency of record, a move intended to strengthen marketing for its obesity portfolio but unlikely to materially affect near-term earnings. Novo Nordisk makes Omnicom agency of record for US media buying
• Negative Sentiment: Wegovy pill sales totaled about $497 million, narrowly missing forecasts. Investors remain concerned that the launch is not progressing rapidly enough to offset slowing momentum in Novo’s injectable obesity products. Novo Nordisk CEO addresses investor expectations after Wegovy pill sales miss forecasts
• Negative Sentiment: Eli Lilly’s stronger obesity-drug performance is widening the perceived competitive gap. Analysts also point to U.S. pricing pressure, patent losses, slower product development and pipeline impairments as reasons the raised outlook has not fully changed the negative narrative around Novo’s obesity business. The divide between Eli Lilly and Novo Nordisk is widening